Fundraising Fox
/Companies
Sign in

GreenJay Therapeutics

Houston, US · Founded 2022 · 1 known investors

Find your way into GreenJay Therapeutics

Sign up to see every warm intro you have to GreenJay Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the GreenJay Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

GreenJay Therapeutics is a late-stage pharmaceutical company reformulating existing drugs to improve clinical outcomes for hematological diseases. Its lead product, Bulanta, is a new intravenous busulfan formulation that removes a Class 2 solvent to reduce toxicity, initially targeting chronic myelogenous leukemia patients undergoing stem cell transplantation.

BiotechHealthtech

Founders & leadership

VT
Vassil TzenovVice President & Chief Financial Officer
DP
Donald PayneCEO (deceased)
TL
Tommy LeeNamed on SEC filing
MT
Michael Thomas RedmanNamed on SEC filing
BA
Borje AnderssonNamed on SEC filing
JD
James Donald PayneNamed on SEC filing

Investors · 1

Funding

SEC filings, press & company announcements

$1M disclosed across 1 of 3 rounds · 2023–2025

▶$1MofferedApr 2024 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Tommy L LeeDirector
  • Borje S AnderssonDirector
  • Michael T RedmanDirector
  • James Donald PayneExecutive Officer
Offering amount
$1M
Minimum investment
$10K
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedJun 2023 · 27 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Tommy LeeDirector
  • Michael Thomas RedmanExecutive Officer, Director
  • Borje AnderssonDirector
  • James Donald PayneExecutive Officer
Offering amount
$1M
Amount sold
$1M
Minimum investment
$5K
First sale
Jan 2023
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does GreenJay Therapeutics do?
GreenJay Therapeutics is a late-stage pharmaceutical company reformulating existing drugs to improve clinical outcomes for hematological diseases. Its lead product, Bulanta, is a new intravenous busulfan formulation that removes a Class 2 solvent to reduce toxicity, initially targeting chronic myelogenous leukemia patients undergoing stem cell transplantation.
Who are GreenJay Therapeutics's investors?
GreenJay Therapeutics's investors include Central Texas Angel Network.
How much funding has GreenJay Therapeutics raised?
GreenJay Therapeutics has disclosed $1M raised across 1 of its 3 known rounds.
Where is GreenJay Therapeutics headquartered?
GreenJay Therapeutics is headquartered in Houston, US.